Core Insights - The event held on September 11 focused on the performance explanation of Tianjin-listed companies and highlighted the achievements of Lifesun Pharmaceutical in drug development since 2020 [1] Company Developments - Lifesun Pharmaceutical has made significant progress in new product research and development, with multiple drug approvals achieved [1] - The company has received drug registration certificates for 13 generic products, including Valsartan Amlodipine and Rivaroxaban tablets [1] - A total of 22 product specifications have passed consistency evaluations, and 9 chemical raw material drug applications have been approved [1] Market Strategy - The company aims to enrich its product structure and enhance its marketing system, leading to increased product sales and market share [1] - Lifesun Pharmaceutical is committed to deepening the synergy between research and industrialization to provide accessible quality medications for patients while creating long-term value for investors [1]